NXI Therapeutics intends to commence operations with screening and preclinical development of compounds that interfere with coronin 1-dependent T cell activation in autoimmune diseases and organ transplantation. A biomarker and a diagnostic program targeted towards the development of assay systems to analyse the effectiveness of the therapy and naïve T cell populations for use in patients undergoing immunosuppression is optional.